著者

三星 知 山田 仁志 山崎 修治 小林 真理子 上野 和行 長井 一彦

出版者

公益社団法人 日本薬学会

雑誌

YAKUGAKU ZASSHI (ISSN:00316903)

巻号頁・発行日

vol.140, no.7, pp.943-947, 2020-07-01 (Released:2020-07-01)

参考文献数

19

被引用文献数

1

---

Concomitant therapy with acetaminophen (APAP) and low-dose aspirin is often used in clinical settings; however, it is unclear whether this combination is involved in the progression of chronic kidney disease (CKD). We hypothesized that concomitant therapy with APAP and low-dose aspirin may cause CKD progression. We carried out a retrospective 6-year cohort study that included all patients who received low-dose aspirin from January 2011 to December 2016 at Kaetsu Hospital. Primary outcome was defined as CKD progression at the end of the study compared with baseline. Among the 441 patients treated during the study period, we identified 89 cases of CKD progression. Multivariate regression analysis showed that exposure to APAP>50 g [odds ratio (OR), 2.68, 95% confidence interval (CI), 1.08-6.70], age increase by 1 year (OR, 1.05, 95% CI, 1.02-1.08), and diabetes mellitus (OR, 2.40, 95% CI, 1.41-4.08) had positive associations with CKD progression. Our findings suggested that concomitant therapy with APAP and low-dose aspirin increased the risk of CKD progression. Therefore, we recommend more thorough monitoring of serum creatinine when patients are on such concomitant therapy. Moreover, it is important to advise users of low-dose aspirin to avoid unnecessary use of APAP, in order to reduce the risk of CKD progression.

著者

鎌倉 令 山田 優子 岡村 英夫 野田 崇 相庭 武司 里見 和浩 須山 和弘 清水 渉 相原 直彦 上野 和行 鎌倉 史郎

出版者

一般社団法人 日本不整脈心電学会

雑誌

心電図 (ISSN:02851660)

巻号頁・発行日

vol.31, no.2, pp.150-157, 2011 (Released:2011-08-02)

参考文献数

11

被引用文献数

4 2

---

ベプリジルの至適投与量,ならびに安全かつ有効な血中濃度域を見いだすために,不整脈に対してベプリジルを投与した112例(男性80例,女性32例,年齢64.3±12.5歳)の血中濃度を測定した.測定には高速液体クロマトグラフィー(HPLC)法を用い,臨床的特徴,心電図指標などを対比し,不整脈抑制効果と副作用の発生状況を評価した.平均投与量は128±34 mg/日,平均血中濃度は751±462ng/mlであり,200mg投与群では有意に高い血中濃度(1,093±721ng/ml)を示した.平均観察期間899日で,心房頻脈性不整脈109例中14例が洞調律を維持し,57例で自覚症状が改善した.改善例の血中濃度は非改善例に比べ有意に高かった(866±541ng/ml vs. 622±329ng/ml, p=0.006).副作用としてQTc延長>0.48秒を10例に,徐脈を6例に認めたが,それらの濃度は副作用のない群に比して有意に高かった(QTc延長vs.副作用なし : 1,086±471ng/ml, p=0.005,徐脈vs.副作用なし : 1,056±522ng/ml, p=0.03).Torsade de pointesを呈した例はなかった.【結論】日本人のベプリジル至適投与量は150mg/日以下,症状を改善し,かつ副作用が出現しにくい血中濃度域は600~1,000 ng/mlと考えられた.

著者

小林 貴志 福本 恭子 土下 喜正 楠本 正明 上野 和行

出版者

一般社団法人日本医療薬学会

雑誌

医療薬学 (ISSN:1346342X)

巻号頁・発行日

vol.32, no.8, pp.772-775, 2006-08-10 (Released:2007-11-09)

参考文献数

11

---

It has been reported that the pharmacokinetics and pharmacodynamics of carvedilol vary between the S- and R- enantiomers. The aim of this study was to evaluate the pharmacokinetic characteristics of carvedilol for each enantiomer and apply this in clinical practice. Serum stereoselective concentrations of carvedilol were monitored in 60 Japanese inpatients who received a fixed dose of carvedilol. The concentrations were determined by high performance liquid chromatography (HPLC). Serum carvedilol concentration/dose of administered carvedilol ratios were determined for each enantiomer (R/D, S/D). The means±SD for R/D and S/D were 85.8±264.0 (10-3kg/L) and 29.0±78.2 (10-3kg/L), respectively. The mean for R/D tended to be larger than that for S/D (p=0.11), and the dispersion of R/D was significantly greater than that of S/D (p<0.01). Although a significant positive correlation was observed between R/D and S/D, a remarkable difference was observed in a few inpatients. These results suggest that the pharmacokinetics of carvedilol are different for each enantiomer. The monitoring of the stereoselective pharmacokinetics of carvedilol is therefore necessary to ensure proper use.

著者

上野 和行 福本 恭子 三星 知 本田 裕加 五十嵐 幸子 長井 一彦 岡島 英雄

出版者

日本食生活学会

雑誌

日本食生活学会誌 (ISSN:13469770)

巻号頁・発行日

vol.25, no.2, pp.101-104, 2014 (Released:2014-10-30)

参考文献数

11

被引用文献数

1 1

---

The Effects of a brown rice diet on clinical laborator y data in cholesterolemia patients (n=20, 2 men and 18 women) were studied. They had been diagnosed with cholesterolemia having over a 180 mg/dL total cholesterol level and received HMG-CoA reductase inhibitors for treatment of their cholesterolemia. All of the patients usually ingested a polished rice diet. They ingested a brown rice diet instead of a polished one 2 out of 3 meals ( breakfast, lunch and dinner ) for 3 months. The mean levels of the total cholesterol and LDL-cholesterol after the study had significantly decreased more than those before the stud y. There was a tendency that the triglyceride after the study had decreased. Also, the mean levels of serum creatinine and blood urea nitrogen after the study had significantly decreased more than those before the study. These results suggested that the ingestion of a brown rice diet suppor ts health care by improving lipidsis in cholesterolemia.

著者

上野 和行

出版者

じほう

雑誌

月刊薬事 (ISSN:00165980)

巻号頁・発行日

vol.47, no.11, pp.1821-1829, 2005-10